Roundtable Discussion: Exploring What More Needs to be Done to Develop & Establish Hippo Pathway Biomarkers

Time: 12:45 pm
day: Conference Day One


  • How do we find evidence for target/pathway regulation biomarkers?
  • Does inhibiting TEAD create a measurable functional effect on disease that could act as a biomarker?
  • Are we selecting the right patients with the right TEAD isoform mutations?
  • Are there biomarkers of resistance and how do we find them?
  • What is the feasibility for clinical biomarker assays?